Background and purpose: For secondary prevention of cardiogenic cerebral embolism with nonvalvular atrial fibrillation (CE-NVAF), non-vitamin K antagonist oral anticoagulants (NOACs) have become popular. This study sought to evaluate the current status of choice of oral anticoagulants (OACs), including warfarin, dabigatran, rivaroxaban, and apixaban. Methods: We studied a total of 197 patients with CE-NVAF who had been treated in our institute between June 2012 and February 2015. Among these, 80 patients were also examined who were treated between March 2014 and February 2015, when three NOACs had been available equally. Results: In the 197 patients, warfarin was chosen for 69 patients (35.0%) and NOACs for 100 (50.8%). Switching from NOACs to warfarin during followup was made in nine patients (9%) with severe disability. Compared to warfarin, NOACs were preferentially chosen for the patients with lower severity, better renal function, and better prognosis. In the 80 patients, multiple comparison tests among three NOACs showed statistical difference on initial National Institutes of Health and Stroke Scale score between rivaroxaban and apixaban groups. Conclusion: The present study revealed that the NOACs were chosen not only medically but also socioeconomically by attending physicians, which may suggest that public education of anticoagulation therapy is important for primary care doctors, pharmacists, and caregivers including patients’ family.
View full abstract